Ivabradine: pre-clinical and clinical evidence in the setting of ventricular arrhythmias.

Abstract

BACKGROUND:

Ivabradine, an agent lowering the heart rate, acting as a funny current (If) specific inhibitor, is responsible for the sinoatrial node's spontaneous depolarization. According to current guidelines, it is indicated in specific heart failure populations and as a second-line treatment option to improve angina in chronic coronary syndromes.

REVIEW OF LITERATURE:

The role of ivabradine in the setting of ventricular arrhythmias has been studied in both experimental and clinical studies. Specifically, experimental studies have examined the role of ivabradine in acute myocardial ischemia, reperfusion, digitalis-induced ventricular arrhythmias, and catecholaminergic polymorphic ventricular tachycardia showing promising results. In addition, clinical studies have shown a beneficial role of ivabradine in reducing ventricular arrhythmias. Ivabradine reduced premature ventricular contractions in combination with beta-blockers in dilated cardiomyopathy patients. Similarly, in catecholaminergic polymorphic ventricular tachycardia, ivabradine reduced dobutamine-induced premature ventricular complexes and improved ventricular arrhythmias burden. On the other hand, current data show no beneficial role of ivabradine in reducing ventricular arrhythmias in myocardial ischemia.

CONCLUSIONS:

Randomized clinical trials are needed to elucidate the role of ivabradine in reducing the burden of ventricular arrhythmias in various clinical settings. HIPPOKRATIA 2022, 26 (2):49-54.

• Authors: G Bazoukis, B Hill, G Tse, K K Naka
• Journal: Hippokratia (Hippokratia) 2022 Apr-Jun Vol. 26 Issue 2 Pg. 49-54 ISSN: 1108-4189 [Print] Greece
• PMID: 37188047 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2022, Hippokratio General Hospital of Thessaloniki.